Abstract Library

#3047 Functional Consequence of β-Arrestin 1 Gene Knock-Out in Pancreatic Neuroendocrine Tumor Cell Line BON-1

Introduction: An important limiting factor influencing treatment efficacy of neuroendocrine tumors (NETs) with somatostatin analogs (SSA) is the availability of somatostatin receptors (SSTR) on NETs. While downregulation or altered pattern of SSTR expression are important considerations, receptor internalization/desensitization by β-arrestins may be a crucial contributing factor. Interestingly, our previous study showed a preferential higher expression of β-arrestin 1 (ARRB1), in gastroenteropancreatic NETS (GEP-NETs) compared to pituitary adenomas.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Iyer A

Authors: Iyer A, Vriens J, Dogan-Oruç F, van Koetsveld P, Hofland L,

Keywords: β-arrestin 1, CRISPR-Cas9, BON-1, knock-out, SSTR, SSA, Pan-NET,

#3028 Pancreatic Neuroendocrine Neoplasms: Dissecting the Molecular Heterogeneity

Introduction: Pancreatic neuroendocrine neoplasms (PNENs) are a group of rare but biologically and clinically heterogeneous neoplasms with variable patient outcomes. Little is known about the molecular differences between PNENs and the biologic significance of such divergence.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Yang K, Kalloger S, Aird J, Lee M, Colborne S,

Keywords: Pancreatic neuroendocrine neoplasms, Exome, Transcriptome, Proteome,

#3007 An mRNA-based Classifier Identifies PanNETs with Different Clinicopathological Characteristics

Introduction: Pancreatic neuroendocrine tumors (PanNETs) are a heterogeneous group of neoplasms that varies from indolent to highly aggressive diseases. Previous studies have suggested alterations of ATRX/DAXX as biomarkers of dismal prognosis, yet inconclusive data (especially in the metastatic setting) prevent those biomarkers to be used as routine clinical tests.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Vicentini C, Barbi S, Bersani S, Rusev B, Lawlor R,

Keywords: PanNET, gene expression profile, ATRX/DAXX mutations, patients’ stratification.,

#2982 Comprehensive Molecular Analysis Identifies Driver Mutations in Metastases of Sporadic Well-Differentiated Neuroendocrine Tumours of the Small Intestine

Introduction: Small intestinal neuroendocrine tumours (SI-NETs) represent a heterogenous group of tumours. The molecular mechanisms which contribute to progression of SI-NETs are poorly elucidated. They are considered to be molecularly distinct from neuroendocrine carcinomas (NECs), which share oncogenic pathways with adenocarcinomas.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Samsom K

Authors: Samsom K, van Veenendaal L, Roepman P, Kodach L, Steeghs N,

Keywords: whole genome sequencing, neuroendocrine tumour, small intestine, genetics,

#2975 Next Generation Sequencing of Pancreatic Neuroendocrine Tumors in Russian Cohort

Introduction: The appearance of next generation sequencing (NGS), - a powerful high-performance method, allowed accumulation of a large amount of information concerning genetic and epigenetic patterns, however, the problem of matching clinical, histological picture with genetic structure in pNETs remains open.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Trifanov V

Authors: Trifanov V, Kit O, Timoshkina N, Gvaldin D, Karnauhov N,

Keywords: Next generation sequencing, pancreatic neuroendocrine tumors,